key: cord-0928025-wlrnzk1m authors: Kow, Chia Siang; Hasan, Syed Shahzad title: Potential interactions between COVID-19 vaccines and antiepileptic drugs date: 2021-02-05 journal: Seizure DOI: 10.1016/j.seizure.2021.01.021 sha: c2ba3c4634e7e0b334f846bc65eadd921bfcce8c doc_id: 928025 cord_uid: wlrnzk1m nan This is a PDF file of an article that has undergone enhancements after acceptance, such as the addition of a cover page and metadata, and formatting for readability, but it is not yet the definitive version of record. This version will undergo additional copyediting, typesetting and review before it is published in its final form, but we are providing this version to give early visibility of the article. Please note that, during the production process, errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain. Fırat et al. [1] discussed the potential drug-drug interactions between antiepileptic drugs and therapeutic drugs currently used in the management of coronavirus disease 2019 (COVID-19). This piece of discussion is relevant and indeed is of utmost importance given that clinicians specialized in the management of COVID-19 may not be familiar with the use of antiepileptic drugs and thus they may be of little knowledge how best to manage the potential drug-drug interactions involving antiepileptic drugs and the therapeutic drugs for COVID-19. While we compliment the effort by Fırat et al. [1] , we believe that in the current context where COVID-19 vaccines had been administered to the public in few countries, and soon to be distributed all around the world, we should discuss the potential interactions between COVID-19 vaccines and antiepileptic drugs. Many may not know that vaccines could modify the metabolism of the drug in the human body. Upon vaccination, an immune response that closely replicates the natural immune response to the infectious disease would be elicited, which serves to protect against the infection by the same or closely related pathogens. In contrary to our common belief, such an immune response does not merely involve the humoral arm of the immune system where B lymphocytes are triggered to produce antibodies, but also the cellular arm of immunity mediated by T lymphocytes to produce cytokines, most notably interferongamma [2] . Specifically, administration of the COVID-19 vaccine BNT162b2 elicited strong antibody responses alongside robust CD4+ and CD8+ T-cell responses, where the expansion of CD4+ and CD8+ T cells was observed, with a high fraction of these spike (S) protein-specific T-cells producing interferon-gamma [3] . In addition, administration of the COVID-19 vaccine mRNA-1273 CD4+ also elicited T-cell responses that produced interferon-gamma upon stimulation with S-specific peptides [4] . T-cell responses with the production of interferon-gamma are not specific to mRNA vaccines (BNT162b2, mRNA-1273), in which the vector-based COVID-19 vaccine ChAdOx1 nCoV-19 had been demonstrated to elicit similar responses [5] . Cytokines such as interferon-gamma could lead to reduced expression of cytochrome P450 (CYP) enzymes. An In vitro study [6] with human hepatocytes reported that exposure to interferon-gamma led to downregulation of CYP 1A2 and CYP 3A4. In addition, activities of CYP enzymes, as measured by the erythromycin breath test, inversely correlated with interferon-gamma production after administration of vaccine [7] . However, not all CYP enzymes could be affected by the production of interferon-gamma, wherein in vitro studies demonstrated that human hepatocytes treated with interferon-gamma had reduced expression for CYP 1A2, CYP 2C8, CYP 3A4, CYP 2B6, CYP 2E1, but no effect on the expression for CYP 2C9, CYP 2C19, and CYP 2C18 [6, 8, 9] . Antiepileptic drugs vulnerable to interactions with COVID-19 vaccines include carbamazepine, which is metabolized by the hepatic CYP 3A4 enzymes [10] . There had been a case report [11] of carbamazepine toxicity that developed 13 days following administration of the influenza vaccine. Besides, a case series [12] found that serum phenytoin levels that increased temporarily by 46-170% in certain patients could best be attributed to the influenza vaccination. The interaction with phenytoin is probably not as significant compared to carbamazepine since it is largely metabolized by CYP 2C9 and CYP 2C19 which the levels are not affected by interferon-gamma, while a minor fraction is metabolized by CYP 2C8 [10] . In another prospective study [13] of 55 patients, mean serum concentrations of phenytoin and phenobarbital were significantly higher than baseline on day 7 after administration of influenza vaccine, while mean serum concentration of carbamazepine significantly increased from day 7 to day 14 after administration of influenza vaccine. Of note, phenobarbital is largely metabolized by hepatic CYP 2C9 with minor metabolism by CYP 2C19 and CYP 2E1 [10] . Other antiepileptic drugs such as ethosuximide (metabolized by CYP 3A4, CYP 2E), clonazepam (metabolized by CYP 3A4), felbamate (metabolized by CYP 3A4, CYP 2E1), tiagabine (metabolized by CYP 3A4), and zonisamide (metabolized by CYP 3A) may also be susceptible to the interaction with COVID-19 vaccines, though there are no previous reports of drugvaccine interaction involving these drugs [10] . Although the current studies involve interactions between influenza vaccines and antiepileptic drugs, it appears reasonable to assume that the same could occur with COVID-19 vaccines due to interferongamma production from T-cell responses by COVID-19 vaccines. Certainly, more studies are needed to investigate the potential interactions between COVID-19 vaccines and antiepileptic drugs, including if the effects differ between different types of COVID-19 vaccines. However, our concerns of potential interactions between COVID-19 vaccines and antiepileptic drugs should not be interpreted as the reason for patients with epilepsy to avoid COVID-19 vaccination or that the COVID-19 vaccination would be less effective. Instead, in the meantime, the clinicians should be vigilant towards such interactions, and patients should be advised to report symptoms of hypertoxicity, before the establishment of the clinical relevance of our concerns in the future studies. No funding or sponsorship was received for the publication of this article. All named authors declare that they have no potential conflict of interest. J o u r n a l P r e -p r o o f COVID-19 & antiepileptic drugs: Should we pay attention? Cytokine production after influenza vaccination in a healthy elderly population BNT162b2 induces SARS-CoV-2-neutralising antibodies and T cells in humans An mRNA Vaccine against SARS-CoV-2 -Preliminary Report Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1/2, single-blind, randomised controlled trial Nitric oxide-mediated inhibition of cytochrome P450 by interferon-gamma in human hepatocytes Effect of influenza immunization on CYP3A4 activity in vivo Gene-specific effects of inflammatory cytokines on cytochrome P450 2C, 2B6 and 3A4 mRNA levels in human hepatocytes Suppression of cytochrome P450 2E1 promoter activity by interferon-gamma and loss of response due to the -71G>T nucleotide polymorphism of the CYP2E1*7B allele Genetic polymorphisms associated with antiepileptic metabolism Carbamazepine toxicity after influenza vaccination Increased serum phenytoin concentration following influenza vaccination Effect of influenza vaccine on serum anticonvulsant concentrations